Sweden-based Olink Holding AB specializes in developing, producing, and marketing biotechnological products and services to enhance proteomics research. The company offers solutions for protein biomarker discovery, aiming to accelerate proteomics research to enhance human health insights and disease treatment. The company’s products include the Olink Explore series for protein studies in multiple disease areas, Olink Target and Olink Flex for targeted and wider biomarker analysis, respectively, and Olink Focus for personalized solutions for specific proteins. It also provides analytical and bioinformatics services, including Olink Signature Q100, which is a qPCR readout platform for precise protein quantification, Olink NPX software for data processing, modeling, and visualization, and Olink Insight cloud platform, which enables data analysis and collaboration among researchers.
In October 2023, Olink was acquired by Thermo Fisher Scientific, becoming a part of Thermo Fisher’s Life Sciences Solutions segment. However, the company continued to operate as an independent entity. In March 2021, Olink was listed on Nasdaq.
Key customers and partnerships
Olink caters to academic institutions, government bodies, and biopharmaceutical companies, providing tools and services for life sciences research.
Funding and financials
In January 2023, Olink raised USD 117 million in a private equity round. In October 2023, when it was acquired by Thermo Fisher Scientific, Olink was valued at ~USD 3.1 billion. Olink generated USD 169.6 million revenue in 2023, increasing at a three-year CAGR of 46% (21% YoY growth). Its operating margin ranged between -47% and -29.6% over 2021–2023.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.